BOSTON – DeepCure, a pioneering force in AI-driven drug discovery focused on novel small molecule therapeutics, today announced the successful closing of a $24.6 million Series A-1 financing round. This significant investment was spearheaded by Iag Capital Partners, a private investment firm known for its strategic investments in early-stage, high-impact companies, with continued participation from DeepCure’s existing investors. This latest round brings DeepCure’s total funding to over $72 million since its inception, underscoring strong investor confidence in its innovative approach.
This financial boost marks a pivotal moment for DeepCure, enabling the company to further refine its cutting-edge technology and accelerate the development of its robust pipeline in immunology and inflammation towards crucial clinical trials. The leadership at DeepCure expresses enthusiasm about this new partnership. “IAG Capital Partners is highly regarded for its profound understanding of the technology landscape and its ability to identify innovations poised to make a significant difference,” stated Kfir Schreiber, CEO and Co-Founder of DeepCure. “Our team is eager to leverage their extensive experience, and we are delighted to welcome Dr. Ehsan Jabbarzadeh to our Board of Directors. We also deeply appreciate the ongoing commitment from our current investors.”
DeepCure stands out due to its groundbreaking engine that combines generative AI and physics-based modeling to revolutionize the discovery of small molecule therapies, particularly for challenging and previously undruggable targets. This sophisticated engine excels at mapping potential interaction sites on protein surfaces and designing novel, synthesizable molecules with promising lead-like characteristics. Complementing this AI prowess is DeepCure’s development of the world’s most advanced automated chemistry synthesis platform. This platform dramatically accelerates the speed, volume, and diversity of molecules that can be synthesized and tested, significantly enhancing the efficiency of the drug discovery process.
Dr. Jabbarzadeh, Venture Partner at IAG Capital Partners, commented on the investment, “DeepCure has achieved remarkable technological advancements in both AI and automated chemistry synthesis, effectively addressing critical bottlenecks in small molecule drug discovery.” He further emphasized the potential impact, noting, “These breakthroughs are crucial for targeting a vast array of intractable targets that are known to play a central role in the progression of various diseases.” Alex Kash, Associate at IAG Capital Partners and board observer, echoed this sentiment, highlighting the transformative potential of DeepCure’s technology.
The infusion of capital from this Series A-1 financing will be instrumental in propelling DeepCure’s pioneering technology to new heights. A primary focus will be on advancing its pipeline of immunology and inflammation programs. These programs are strategically aimed at addressing significant unmet medical needs and bringing first-in-class and best-in-class treatments to patients. Jason Dinges, Morningside Technology Advisory and a DeepCure board member, added, “These additional funds will empower us to expedite our progress, moving DeepCure’s innovative programs in inflammation and immunology closer to clinical validation. We are particularly excited about the potential of these programs to address the underserved needs of a large patient population.”
About IAG Capital Partners
IAG Capital Partners is a distinguished private investment group headquartered in Charleston, South Carolina. The firm is dedicated to investing in early-stage companies, fostering partnerships with visionary leaders, and building impactful companies that are poised to improve lives and shape the future. Their investment philosophy centers around identifying and supporting companies with groundbreaking technologies and strong growth potential.
About DeepCure
DeepCure, originating from the innovative labs of MIT, is committed to accelerating the development of breakthrough therapies through the application of artificial intelligence (AI) and related technologies to transform small molecule drug discovery. Based in Boston, MA, DeepCure fosters a collaborative environment where engineers, chemists, and biologists work together to tackle complex challenges and develop solutions that will have a profound and positive impact on patient health worldwide. For further information, please visit www.deepcure.ai.
Media Contact
Colin Sanford
[email protected]
